Investigation of the survival time and quantification of therapeutic benefits for HIV patients with highly active antiretroviral therapy.

被引：0

作者：

Lv, Riying ^{[1
,2
]}

Li, Guojian ^{[1
]}

Wu, Jizhou ^{[3
]}

Zhu, Yujia ^{[2
]}

Li, Jianlong ^{[4
]}

Qin, Xionglin ^{[4
]}

Li, Shixiong ^{[2
]}

Fu, Shaoping ^{[2
]}

Qin, Qiongfen ^{[2
]}

Xu, Chaoyu ^{[2
]}

机构：

[1] Guangxi Med Univ, Nanning, Peoples R China

[2] Guangxi Med Univ, Affiliated Hosp 8, Dept Infect Dis, Guigang, Peoples R China

[3] Guangxi Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanning, Peoples R China

[4] Guangxi Guigang City Ctr Dis Control, Guigang, Peoples R China

来源：

BIOMEDICAL RESEARCH-INDIA | 2017年 / 28卷 / 01期

关键词：

HIV; Survival time; Antiretroviral therapy; Retrospective analysis; CD4+T cells; INHIBITORS; RESISTANCE; AIDS; MICE;

D O I：

暂无

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Introduction of highly active antiretroviral therapy (HAART) has been proved to be very effective against HIV infection and AIDS progression. It has made a great contribution to decrease both HIV-induced AIDS mortality and morbidity. In this study, we aim to investigate the efficiency of HAART as the treatment for newly diagnosed HIV patients as well as survival time of patients. 3100 cases of newly diagnosed HIV patients receiving HAART were selected in this study for a period of 12 months. The level of viral RNA, numbers of CD4+ T cell and death cases were recorded monthly. With the 12 months of HAART treatment, the net increased numbers of CD4+ T cell were of 4.3 x 10(3) cell/ml in average (P<0.01). Viral load dropped to an undetectable level (below to 1.70 log copies/mL) after 8 months treatment. In conclusion, HIV/AIDS patients received significantly benefits by administrating HAART.

引用

页码：279 / 283

页数：5

共 17 条

[1] Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket [J].

Bai, Yu ;

Xue, Huifang ;

Wang, Kun ;

Cai, Lifeng ;

Qiu, Jiayin ;

Bi, Shuangyu ;

Lai, Luhua ;

Cheng, Maosheng ;

Liu, Shuwen ;

Liu, Keliang .

AMINO ACIDS, 2013, 44 (02) :701-713

[2]

Barre-Sinoussi F, SCI J, V983, P868

[3]

Das K, 2013, CURR OPIN VIROL, V3, P119, DOI 10.1016/j.coviro.2013.03.014

[4] HIV-1 reverse transcriptase and antiviral drug resistance. Part 1 [J].

Das, Kalyan ;

Arnold, Eddy .

CURRENT OPINION IN VIROLOGY, 2013, 3 (02) :111-118

[5] Emerging Concepts in the Immunopathogenesis of AIDS [J].

Douek, Daniel C. ;

Roederer, Mario ;

Koup, Richard A. .

ANNUAL REVIEW OF MEDICINE, 2009, 60 :471-484

[6]

Gallo RC, 1983, SCI J, V20, P865

[7]

Métifiot M, 2013, ADV PHARMACOL, V67, P75, DOI 10.1016/B978-0-12-405880-4.00003-2

[8] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].

Michaels, SH ;

Clark, R ;

Kissinger, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) :405-406

[9] Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata [J].

Palella, FJ ;

Deloria-Knoll, M ;

Chmiel, JS ;

Moorman, AC ;

Wood, KC ;

Greenberg, AE ;

Holmberg, SD .

ANNALS OF INTERNAL MEDICINE, 2003, 138 (08) :620-626

[10] SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS OF ZIDOVUDINE-RESISTANT ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS [J].

RICHMAN, DD .

AMERICAN JOURNAL OF MEDICINE, 1990, 88 (5B) :S8-S10

← 1 2 →